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ABSTRACT
Resveratrol is a polyphenol that has witnessed an unprecedented yearly growth 
in PubMed citations since the late 1990s. Based on the diversity of cellular processes 
and diseases resveratrol reportedly affects and benefits, it is likely that the interest in 
resveratrol will continue, although uncertainty regarding its mechanism in different 
biological systems remains.
We hypothesize that insights on disease-modulatory activities of resveratrol 
might be gleaned by systematically dissecting the publicly available published data 
on chemicals and drugs. In this study, we tested our hypothesis by querying DTome 
(Drug-Target Interactome), a web-based tool containing data compiled from open-
source databases including DrugBank, PharmGSK, and Protein Interaction Network 
Analysis (PINA). Four direct protein targets (DPT) and 219 DPT-associated genes 
were identified for resveratrol. The DPT-associated genes were scrutinized by 
WebGestalt (WEB-based Gene SeT Analysis Toolkit). This enrichment analysis resulted 
in 10 identified KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways. Refined 
analysis of KEGG pathways showed that 2 — one linked to p53 and a second to prostate 
cancer — have functional connectivity to resveratrol and its four direct protein targets. 
These results suggest that a functional activity network (FAN) approach may be 
considered as a new paradigm for guiding future studies of resveratrol. FAN analysis 
resembles a BioGPS, with capability for mapping a Web-based scientific track that 
can productively and cost effectively connect resveratrol to its primary and secondary 
target proteins and to its biological functions.
INTRODUCTION
Resveratrol is a stilbenoid present abundantly in red 
wine, red grape skin, peanuts and several other food items 
and drinks consumed daily. Interest in resveratrol increased 
greatly following the report by Jang et al. in 1997 showing 
that it displays chemopreventive activities as evidenced by 
the inhibition of carcinogenesis using in vitro experiments 
and animal model studies [1]. Resveratrol has also been 
shown to have beneficial effects on coronary heart diseases, 
the aging process, pathological inflammation, and ischemic 
and chemically induced injuries. Resveratrol-mediated 
bioactivities are of significant public health interest; 
accordingly, research focus in recent years has been directed 
to the understanding of its mechanisms and identification of 
its primary (direct) and secondary (indirect) targets [2–11]. 
What approach is most appropriate and relevant for the 
systematic dissection of the rich published research data on 
resveratrol to generate insightful, definitive and predictive 
leads, and not merely random clues typically associated 
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with a hit-and-miss strategy? Can this approach also 
compare experimental findings from the same or different 
laboratories, insofar as the functional interpretation of 
changes in large gene sets for possible extrapolation into 
common or unique underlying biological themes?
In recent years, the successful launch and 
implementation of numerous multi-center genomics studies, 
encompassing the use of microarrays, proteomics, and other 
high-throughput screening assays often produce hundreds 
to thousands of intriguing gene hits which can present 
formidable challenges for integration, phenotypically or 
thematically. A possible solution to this analytical obstacle 
in data mining may lie in the use of the network-based 
approach — a simple yet effective method that has found 
application in the analysis of massive data obtained from 
numerous human disease studies designed to explore and 
connect the relationship existing between a drug and its 
targets and interacting proteins, for association with disease 
[12–15]. DTome is a web-based instrument that allows for 
the search and mining of existing drug-target information 
[16]. DTome could provide insight and understanding of the 
molecular mechanisms of drug action as well as a focused 
scope and direction for future research. Whether DTome 
can reveal authentic or teaser leads and generate rational, 
clinically relevant hypotheses for advancing our knowledge 
on chemicals or dietary agents with chemopreventive 
potential remains to be established.
In this study, we introduce a FAN analysis capable 
of effectively analyzing and prioritizing candidate genes 
quickly for linkage to experimentally verifiable grouped 
pathways through the deployment of Web-accessible, open 
portal databases. As test of principle, we applied DTome 
to the widely studied polyphenol resveratrol. We found 
that 3 of its 4 identified direct protein targets are linked 
to the tumor suppressor gene p53. When the readout 
targets and their associated genes were further analyzed 
for functionality through pathway enrichment analysis, 
the p53 pathway was identified as one of top 10 enriched 
KEGG pathways containing 8 resveratrol-associated 
genes. We propose that the DTome-directed FAN analysis 
is a new paradigm for analyzing resveratrol:p53 interplay; 
the flagged genes involved in resveratrol-mediated p53 
control can be experimentally verified and new insights 
on the biological context of activation/restoration of p53 
function by resveratrol might be illuminated. The approach 
has implications for understanding the prevention of 
cancer by resveratrol and can aid in the treatment of 
malignant tumors harboring the dysfunctional p53.
RESULTS
Characterization of bioactivities of resveratrol 
using DTome and visualization of resveratrol-
linkage networks by Cytoscape
In biological systems, chemicals (presented 
as metabolites, drugs, or chemopreventive agents), 
proteins, and genes interact with one another to result in 
a physiologic function at the cellular and organ levels. 
This higher-order, complex interaction among molecules 
can be visualized as a network which typically consists 
of nodes representing biological entities (e.g., gene, 
protein, disease) and edges representing the relationships 
among them (e.g., physical interaction, co-expression 
or co-modulation, shared pathway). We first queried 
DTome using resveratrol as input. This resulted in output 
DB02709 categorizing resveratrol as antioxidants, 
platelet aggregation inhibitors, enzyme inhibitors, anti-
carcinogenic agents, anti-neoplastic agents, phytogenic 
and anti-mutagenic agents. Moreover, using the grouping 
status of resveratrol as an experimental drug, query of 
DTome indicated that it is a chemical investigated for 
the treatment of herpes labialis infections (cold sores) 
(Table 1). Table 2  presents the 4 primary direct protein 
targets (DPT) of resveratrol, respectively, PTGS1, 
CSNK2A1, NQO2 and PTGS2. Expanding our search and 
analysis using the “Get protein-protein interaction (PPI) 
option” in DTome, we identified a total of 219 target-
protein interactions designated DPT-associated genes 
as being related to resveratrol and its 4 primary targets 
(Appendix 1). The data set obtained was then collectively 
integrated for construction of a relevant biological 
network using Cytoscape 2.8 [17]. This resulted in the 
creation of a resveratrol network and the visualization of 
resveratrol target-protein interactions. The 4 primary DPTs 
and their secondary DPT-associated proteins, CSNK2A1 
(202 PPI), NQO2 (4 PPI), PTGS1 (1 PPI) and PTGS2 
(12 PPI), are shown in Figure 1. It should be noted that 
except for PTGS1, the other three primary targets show a 
direct association with control of tumor suppressor gene 
p53 suggesting that a main target pathway under control 
or mediated by resveratrol is connected to p53.
Analysis of functional attributes connected to 
resveratrol-mediated changes in gene sets using 
WebGestalt
To assess functional features of resveratrol-
mediated gene sets, we performed the KEGG pathway 
enrichment analysis embedded in WebGestalt. The top 
10 KEGG pathways linked to resveratrol DPTs and 
their DPT-associated genes include pathways in cancer 
(31 genes), cell cycle (15 genes), MAPK signaling 
(19 genes), Wnt signaling (15 genes), Neurotrophin 
signaling (12 genes), adherens junction (10 genes), 
prostate cancer (10 genes), p53 signaling (8 genes), 
epithelial cell signaling in Helicobacter pylori infection 
(8 genes) and melanogenesis (9 genes) (Table 3). All 
enriched pathways identified using this approach 
represent biological areas that show a statistically 
significant association with resveratrol gene sets thus 
warranting further investigation. Broad grouping 
of the functional analysis suggests that resveratrol 
associated genes are mainly linked to cancer-related and 
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signaling cascade pathways with potential mechanistic 
underpinnings, including (i) control of cancer cell 
proliferation and survival via MAPK/p53 mediated 
cell cycle control, (ii) control of neural or cancer 
stem cell development via neurotrophin signaling, 
and (iii) regulation of gene transcription by Wnt/b-
catenin signaling. Given that 3 of 4 primary targets of 
resveratrol have demonstrated a direct association with 
the p53 axis (Figure 1), emphasis was directed to the 
p53 signaling pathway. Further analyses revealed that 
8 genes in the p53 pathway showed a connection to 
resveratrol-associated genes, PTEN, TP53, CHEK1, 
CDKN1A, BID, CDK1, SFN and IGFBP3 (EntrezGene 
ID: 5728, 7157, 1111, 1026, 637, 983, 2810 and 3486) 
(Table 3). Thus, based on the results of functional 
analysis combined with resveratrol target search, it 
Table 1: Characterization of resveratrol using DTome
DB_ID Name Group Category Indication
DB02709 Resveratrol Experimental Antioxidants Being investigated for 
the treatment of Herpes 










Table 2: Identification of direct targets of resveratrol using DTome
Searched_Drug (1/1) Target (4)
# DB_ID Name Target_Symbol UniProtKB_AC Entrez_ID
1 DB02709 Resveratrol PTGS1 P23219 5742
2 DB02709 Resveratrol CSNK2A1 P68400 1457
3 DB02709 Resveratrol NQO2 P16083 4835
4 DB02709 Resveratrol PTGS2 P35354 5743
Figure 1: Drug-target interactome of resveratrol: DTome based resveratrol drug-target protein interaction network. 
Drug: resveratrol (color in yellow), primary direct protein targets (DPT): CSNK2A1, NQO2, PTGS1 and PTGS2 (color in red) and 
secondary DPT-interacting protein: color in blue. p53 (circle in dash red) is targeted by 3 out of 4 resveratrol direct targets.
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may be suggested that a functional association exists 
between p53 and resveratrol thereby linking DPTs of 
resveratrol with p53 control. In addition, the enriched 
KEGG pathways derived from resveratrol gene sets also 
discovered 10 genes, CREBBP, HSP90B1, CTNNB1, 
PTEN, NFKBIA, TP53, HSP90AA1, CDKN1A, RELA 
and TCF7L2 (EntrezGene ID: 1387, 7184, 1499, 5728, 
4792, 7157, 3320, 1026, 5970 and 6934), all associated 
with prostate cancer (Table 3). It is noteworthy that 
anti-carcinogenic properties of resveratrol have been 
observed in other solid tumors including the highly 
fatal pancreatic cancer [18, 19]. Evidence has also been 
garnered recently that resveratrol demonstrates efficacy 
in the treatment of inflammation-induced pancreatitis 
[20, 21].
Mining genetic alterations connected with 
resveratrol-associated genes, PTEN, TP53 and 
CDKN1A, in prostate cancer by cBio portal
Although DTome proffers resveratrol as the choice 
of treatment for infections (Table 1); the functional 
enrichment analysis uncovers the link between resveratrol 
associated genes and cancer-related pathways (Table 3). 
To further explore the validity of this link, cBio portal, 
a web-based integrated data mining system was used to 
explore the genetic alteration of genes associated with 
resveratrol in prostate cancer. Since the p53 signaling 
pathway is a main target of resveratrol, and because 3 
overlapping genes (PTEN, TP53 and CDKN1A) were 
also found to be associated with prostate cancer by 
Table 3: List of enriched resveratrol associated gene sets identified using KEGG PATHWAYS ANALYSIS
Pathway Name #Gen Entrez Gene (corresponding 
gene set)
Statistics
Pathways in cancer 31
7184 4149 2247 9978 7157 1857 
324 1026 2353 637 6934 2246 
1387 3725 5743 1499 999 5728 
3091 4609 35764792 5371 3065 





1387 7465 9978 4609 7157 
10971 8454 3065 1111 1026 994 
983 7529 2810 3066
C=124;O=15;E=0.63;R=23.93;
rawP=1.08e-16;adjP=5.35e-15
MAPK signaling pathway 19
5058 4149 2247 7157 2353 3925 
1432 3725 2246 4609 408 5971 




Wnt signaling pathway 15
3725 1387 1499 9978 4609 7157 




Neurotrophin signaling pathway 12 3667 3725 805 4792 801 7157 5664 10971 808 5970 1432 7529
C=127;O=12;E=0.64;R=18.69;
rawP=2.65e-12;adjP=5.25e-11
Adherens junction 10 1387 5770 7454 999 1499 1457 1460 6714 1459 6934
C=73;O=10;E=0.37;R=27.10;
rawP=4.17e-12;adjP=6.88e-11
Prostate cancer 10 1387 7184 1499 5728 4792 7157 3320 1026 5970 6934
C=89;O=10;E=0.45;R=22.23;
rawP=3.18e-11;adjP=4.50e-10
p53 signaling pathway 8 5728 7157 1111 1026 637 983 2810 3486
C=68;O=8;E=0.34;R=23.27;
rawP=2.13e-09;adjP=2.34e-08
Epithelial cell signaling in 
Helicobacter pylori infection 8




Melanogenesis 9 1387 805 1499 801 808 1857 1855 6934 1856
C=101;O=9;E=0.51;R=17.63;
rawP=2.55e-09;adjP=2.52e-08
The row lists the following statistics: C: the number of reference genes in the category; O: the number of genes in the 
gene set and also in the category; E: the expected number in the category; R: ratio of enrichment; rawP: p value from 
hypergeometric test; adjP: p value adjusted by the multiple test adjustment
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KEGG analysis embedded in WebGestalt, we utilized 
the 3 indicated overlapping genes identified in both p53 
signaling and KEGG pathways to cross check their cancer 
genomic alterations and clinical profiles in prostate cancer 
(Table 3). A query of 3 selected overlapping genes was 
performed. Among 7 prostate cancer studies analyzed 
[22–27], alterations ranging from 1.9% to 72.1% were 
found for the gene sets/pathways submitted for analysis 
(Figure 2A). A summary of the multiple gene alterations 
observed across each set of tumor samples from the 
Michigan study [24] showing the most pronounced 
genomic changes is presented using OncoPrint. The results 
show that 44 cases (72%) have an alteration in at least one 
of the three genes queried; the frequency of alteration in 
each of the selected genes is shown in Figure 2B. No gene 
alteration occurred in CDKN1A (Figure 2B). For PTEN, 
most alterations are classified as deep deletions with a few 
cases of mutations (Figure 2B). Gene changes associated 
with TP53 include deep deletions and missense/truncating 
mutations (Figure 2B). The alterations in these two genes 
tend towards co-occurrence across samples, however, 
Mutual Exclusivity analysis showed no statistical 
significance (p = 0.183) (data not shown).
cBio portal also provides interactive analysis and 
construct networks to view genes that are altered in 
cancer. Here, we first show the network to contain all 
neighbors of 3 query genes, PTEN, TP53 and CDKN1A 
(Figure 3). Next, to reduce the complexity of network 
analysis, the genomic alteration frequency within the 
selected cancer study was applied as a filter such that 
Figure 2: Mining genetic alterations connected with resveratrol-associated genes, PTEN, TP53 and CDKN1A, in 
prostate cancer studies embedded in cBio cancer genomics portal. A. Overview of changes on PTEN, TP53 and CDKN1A 
genes in genomics data sets available in 7 different prostate cancer studies. B. OncoPrint: A visual summary of alteration across a set of 
prostate samples (data taken from the Michigan studies, Nature 2012) [24] based on a query of the three genes PTEN, TP53 and CDKN1A). 
Distinct genomic alterations including mutations and CNAs (copy number alterations, exemplified by gene amplifications and homozygous 
deletions) are summarized and color coded presented by % changes in particular affected genes in individual tumor samples. Each row 
represents a gene, and each column represents a tumor sample. Red bars designate gene amplifications, blue bars represent homozygous 
deletions, and green squares indicate nonsynonymous mutations.
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only the neighbors with the highest alteration frequency 
in addition to our query genes are shown. This refined 
analysis generated a different complexity of altered 
gene set networks. As a start, the 3 overlapping genes 
(PTEN, TP53 and CDKN1A) were identified when 
neighbors’ ≥53% alteration was applied as the filter. 
Comparatively, 4 genes including androgen receptor 
(AR) were evident using a filter of 28% alteration. 
A 5 gene cluster with AR and retinoblastoma (RB1) 
was observed with a filter incorporating a 27% 
alteration, and 6 genes with the addition of AR, 
RB1 and YWHAZ (tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta) 
were revealed when the filter was reduced to 26% 
alteration (Figure 3). The full and pruned networks 
generated show the potential of complexity as well as 
the variability of difference in interactions between 
resveratrol associated genes most relevant to the genes 
altered in prostate cancer tumor samples from the 
Michigan study [24].
DISCUSSION
Since the landmark finding of the chemoprotective 
activity of resveratrol reported by Jang et al. [1]; more 
than 7600 publications on resveratrol have appeared on 
PubMed to date. A wide range of biological and cellular 
activities and multiple targets have been independently 
identified for resveratrol illustrating the fascinating 
nature of this compound with a plethora of associated 
diseases. Still, how resveratrol promotes its wide range 
of beneficial effects remains incomplete. As such, new 
analytical methods or platforms are needed capable of 
bridging resveratrol to its target proteins for linkage to 
the observed biological effects. In this study, we introduce 
FAN analysis to elucidate the molecular mechanisms of 
resveratrol and its association with clinical outcomes in 
cancer by using a set of web-based tools. FAN analysis 
explores the molecular action of resveratrol by querying 
multidimensional cancer genomics data embedded in two 
open platforms, DTome [16] and cBio portal [28]. This 
Figure 3: A visual display of the gene network connected to PTEN/TP53/CDKN1A in prostate adenocarcinoma (based 
on the Michigan study, Nature 2012) [24]. The data mined from the cBio cancer genomics portal. PTEN, TP53, CDKN1A, and 
resveratrol associated genes, are used as seed genes (indicated with thick black border), to automatically harvest all other genes identified 
as altered in prostate adenocarcinoma (taken from the Michigan study, Nature 2012). Multidimensional genomic details are shown for seed 
genes PTEN, TP53 and CDKN1A. Darker red indicates increased frequency of alteration (defined by mutation, copy number amplification, 
or homozygous deletion) in prostate cancer. Shown in the figure is the full and pruned network containing all or partial neighbors of all 
query genes generated; the filters used included highest genomic alteration frequency within the selected cancer study in addition to the 
query genes.
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workflow combines two simple steps: (i) identify primary 
DPTs of resveratrol and functionally integrate with DPT-
associated proteins using DTome [16] and (ii) explore and 
verify whether genetic alterations exist for the identified 
resveratrol-associated genes/proteins across samples in 
large-scale cancer genomics projects by cBio portal [28]. 
The FAN analysis enables researchers to interactively 
explore effective targets of resveratrol for connectivity 
to information about the biological pathways for all the 
genes linked to resveratrol identified DPTs and DPT-
associated genes and ultimately to clinical outcomes — 
to our knowledge, this is a hitherto unexplored feature 
that translates data set from bench to the bedside, with 
significant certainty of biological plausibility. Moreover, 
FAN analysis also can generate research leads not merely 
driven by hypothesis but transcends to ‘rationalized 
hypotheses’ where postulates designed to deduce 
biological pathways, in terms of gene regulatory networks 
or protein-protein interaction networks, are formulated 
by mining a single or multiple web-based integrated data 
systems. This approach differs significantly from use of 
experimental techniques for determining a few interactions 
at a time, and takes into account findings from perturbation 
studies showing that the suppression of one gene can 
cause the activity of numerous other genes to go up or 
down as implicated in the existence of a cellular network. 
By integrating and utilizing the existing available data 
sources, redundant experiments from the same or different 
laboratories can be reduced and research direction will be 
better guided.
In this paper, we demonstrate the feasibility of FAN 
analysis for connectivity between resveratrol and cancer 
using DTome (for searching the resveratrol target genes) 
combined with cBio portal (for mining alterations of 
resveratrol target genes in cancer). Analysis of resveratrol 
using these two Web-based resources identified 4 
primary DPTs (PTGS1, CSNK2A1, NQO2 and PTGS2) 
(Table 2), 219 secondary DPT-associated genes/proteins 
(Appendix 1) and 10 enriched KEGG pathways linked 
to resveratrol associated genes (Table 3). Based on the 
known functional characteristics of 219 DPT-associated 
genes and our current knowledge of KEGG pathways, 31 
genes may be considered as validated secondary targets of 
resveratrol with mechanistic connectivity to cancer (Table 
3). We surmise that this diverse range of effects is initiated 
by the interplay between resveratrol and its primary DPTs 
positioned at the apex of many cellular events. Since 3 of 4 
primary targets of resveratrol show direct association with 
p53 it is reasonable to suggest that effects of resveratrol are 
primarily mediated by the p53 axis (Figure 1). As support, 
Gene Set Enrichment analysis independently identifies 
the p53 signaling pathway as significantly altered by 
resveratrol (Table 3). The association between p53 and 
the beneficial effects exerted by resveratrol in cancer were 
further explored and evaluated by the genetic alterations 
in 3 overlapping genes (PTEN, TP53 and CDKN1A) 
revealed by resveratrol associated p53 signaling and 
prostate cancer pathways (Table 3). Both PTEN and p53 
are tumor suppressor genes considered to be among the 
most commonly inactivated or mutated in human cancers. 
In the case of prostate cancer, most genetic alterations 
in PTEN and TP53 are deletions or mutations (Figure 
2B), which result in a reduction of their expression in 
concordance with the acceleration of carcinogenesis [29, 
30]. Studies published by us and others suggest that the 
anti-carcinogenic activities of resveratrol are coordinated 
with the activation of p53, concomitant with cell cycle 
control and induction of apoptosis [31–34]. Thus, results 
of FAN analysis are in good agreement with the activation 
of p53 by resveratrol as a major driver for the observed 
beneficial chemopreventive effects on prostate cancer. It 
is worth noting that 70% of men at the time of diagnosis 
with prostate cancer are estimated to have lost a copy of 
the PTEN gene [35]. Since p53 plays a crucial role in 
suppression of PTEN-deficient tumorigenesis via control 
of PTEN transcription [35], we propose that activation 
of p53 by resveratrol is likely to have chemopreventive 
efficacy in patients diagnosed with PTEN-deficient 
prostate cancer.
Another aspect of FAN analysis relevant to its utility 
and implications for the role resveratrol plays in prostate 
cancer relates to the three primary targets of resveratrol: 
CSNK2A1, NQO2 and PTGS2 (Table 2). Although they 
all show association with control of p53, it is not known 
whether they act as sensors, mediators, or capacitors of 
resveratrol. We suggest that DTome-flagged NQO2 is 
especially worth noting since it was independently purified 
and characterized by us as a high affinity resveratrol 
target protein (Kdis=35 nM) using affinity chromatography 
and X-ray analysis [6]. A hypothesis currently being 
considered is that resveratrol acts through NQO2 to 
control prostate cancer cell proliferation and survival 
via regulated interaction with the p53 signaling axis. 
Ongoing studies in our laboratory are directed at charting 
the molecular pipeline emanating from resveratrol to 
NQO2 (its preferred target), followed by the p53 signaling 
network, and ultimately, the pipeline-defined cellular 
fate and phenotype. Demonstration of such a molecular 
pipeline initiated by resveratrol impinging on the p53 axis 
and control of prostate carcinogenesis should illuminate 
new biological insights on the control of cancer harboring 
dysfunctional p53.
In addition to prostate cancer, numerous studies have 
reported on the anti-tumorigenic and chemopreventive 
activities of resveratrol in other solid tumors including 
skin, breast, lung, colon, liver and pancreatic cancers 
[36]. Here, we presented FAN analysis and its utility 
to demonstrate the molecular network bridging the 
connectivity between resveratrol and its primary targets 
as well as resveratrol-associated genes; the functional link 
existing between the revealed pathways/network is likely 
to be biologically associated with the observed effects 
of resveratrol in disease of choice for the analysis, e.g., 
prostate cancer. Whether the connectivity map shown 
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to exist between resveratrol and prostate cancer in this 
work can be extended to other solid tumors remains to 
be investigated. In principle, resveratrol-linkage network 
revealed by query of DTome could apply to a disease 
known to be efficaciously affected by resveratrol, 
provided that the inferred resveratrol-disease associations 
can be confirmed by disease association analysis in 
WebGestalt[16] (Appendix 2) as well as by cross-
validation using disease-specific genetic gene expression 
profile studies [37]. Moreover, the FAN analysis could 
be further expanded to connect resveratrol-associated 
gene sets with cancer-linked, genetic alterations by 
mining cancer-specific databases like cBio Portal [21] 
and/or Oncomine [38, 39]. In addition, it is possible to 
gain insights on the role of resveratrol in the prevention 
of treatment of diseases by exploring alterations 
connected with resveratrol-associated genes by probing 
disease-specific gene expression signatures using data 
embedded in the Gene Expression Atlas of ArrayExpress 
or OMIN (Online Mendelian Inheritance in Man) — a 
comprehensive disease phenotype database of human 
genes and gene disorders [37, 40, 41].
Query of publicly available computational and 
database tools using the automated FAN analysis approach 
may significantly advance (i) understanding of malignant 
disease mechanisms, (ii) facilitate early disease diagnosis 
and improve the accuracy of disease prognosis, and (iii) 
unravel critical roles of resveratrol in human cancers. 
This approach is superior to the manual integration of 
information on resveratrol and its target genes which can 
be challenging, labor-intensive, and error-prone, possibly 
because an extremely large amount of heterogeneous 
data sources must be considered, tested and assayed. 
Comparatively, FAN analysis is completely machine-
readable integrated from heterogeneous sources: DTome, 
KEGG pathway and cBio portal. FAN analysis can be 
used to obtain unified resveratrol-relevant knowledge and 
bring insights into the regulation and control of cancer 
disease processes. By providing a deeper understanding 
of resveratrol’s functions, FAN analysis will also assist 
resveratrol bio-curation and new biological experiment 
design and could significantly accelerate cancer biology 
research. Although generally configured for providing 
primary genomic results rather than clinical associations, 
FAN analysis is extensible and can be readily generalized 
to other biomedical areas. The candidate genes revealed 
can facilitate the interpretation of genomic results for non-
computational biomedical researchers and other users.
Lastly, one can surmise that FAN analysis may 
find application in the repurposing of drugs. Traditional 
drug development faces unique challenges mainly due to 
high cost and long duration for approval of use in clinical 
settings [42]. Accordingly, repositioning of existing 
drugs has taken on increasing appeal and importance as 
an alternative approach. Extensive pharmacokinetic and 
toxicological data also are available for marketed drugs, 
thus providing information which may be readily used to 
guide and position research, and for comparison of data 
generated in studies among laboratories.
Some difficulties remain in applying computational 
learning techniques to problems of predicting chemical/
drug response. These challenges are appropriately summed 
up in one phrase: the intrinsic variability and difficulty 
of reproducibility of biological data. There is significant 
inherent nonrepeatability of experimental conditions and/
or biological phenomena. Quality control on the extremely 
costly equipment used to make biological measurements 
can be a more insidious factor contributing to variability 
and lack of repeatability. To some degree, both factors can 
be in part counteracted by the FAN analysis.
In summary, as advances in research on resveratrol 
using traditional experimental techniques and approaches 
continue, more resveratrol targets will unquestionably be 
identified; nevertheless, the determination as to whether a 
specific biological effect on resveratrol can be definitively 
assigned to individual or simultaneous modulation of 
its newly or established identified targets can remain 
obscure. We believe that some of the uncertainty in 
connecting resveratrol to its targets and subsequent 
phenotype expression can be offset using FAN analysis, 
and that this approach can be used to direct future studies 
with reasonable experimental feasibility for testing and 
validating rationalized hypotheses regarding the effects of 
resveratrol in cancer. For example, a functional network 
can be developed based on the core elements of FAN 
analysis to further evaluate the impact of resveratrol as 
gauged by the changes in altered gene sets shown for a 
specific cancer type or cancer in general by expanding the 
complicity of cBio portal altered gene network (Figure 
3). In addition, drug targets identified and experimentally 
verified through FAN analysis can be used for future drug 
development. Overall, FAN analysis provides a simple 
yet flexible interface to test hypotheses regarding genetic 
alterations in cancer by using existing drug information as 
a guiding BioGPS to aid researchers in translating basic 
research into clinical applications.
MATERIALS AND METHODS
Drug-target search
DTome is a web-based bioinformatic tool able to 
query the information embedded in three open-source 
databases, respectively, DrugBank, PharmGSK, and 
PINA; the data compiled are analyzed, grouped, and used 
to construct a drug-target interactome [16]. Interaction 
networks generated from DTome are integrated into four 
types of relationships: drug-drug interactions, drug-target 
interactions, drug-gene associations, and target-gene-
protein interactions. In this study, DTome was used to 
search the interaction between resveratrol and its targets, to 
generate a resveratrol-target network. The data were then 
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used to construct a visualization chart, followed by further 
analysis and the proposal of validation experiments.
Network generation/visualization and gene set 
enrichment analysis
Through use of the DTome search function, drug-
protein and second level protein-protein interactions 
data were first generated for resveratrol. The data were 
integrated into a resveratrol-mediated network and 
analyzed using Cytoscape (version 2.8.0) [17]. The 
biological information and attribution embedded in 
the generated gene set were analyzed using a web-
based integrated data mining system, WebGestalt [43, 
44]. Biochemical pathways and functions linked to 
the resveratrol gene set were specifically queried and 
navigated by the KEGG pathway enrichment analysis 
tool in WebGestalt [43]. The gene set enrichment 
analysis searches for combinations of features that show 
a significant difference in means between two classes 
that is not an artifact or data noise [45]. Significance in 
the identified gene sets is confirmed by replacing chosen 
significant features (i.e., gene sets) with other genes 
chosen at random, followed by testing and re-analyzing 
to see whether the significant difference still persists. The 
validated significant gene sets were then organized based 
on the KEGG biochemical pathways in a KEGG Table. 
Top 10 pathways with an adjusted P-value less than 0.01 
were selected.
Exploring cancer genomics data linked to 
resveratrol by cBio Cancer Genomics Portal
The cBio Cancer Genomics Portal (http://cbioportal.
org) is an open platform for exploring multidimensional 
cancer genomics data by encapsulating molecular profiling 
data obtained from cancer tissues and cell lines into readily 
understandable genetic, epigenetic, gene expression, and 
proteomic events [28]. Complex cancer genomics profiles 
can be easily accessed using the query interface of the 
portal enabling researchers to explore and compare genetic 
alterations across samples. The underlying data thus 
obtained can be linked to clinical outcomes to facilitate 
novel discovery in biological systems.
In this study, the cBio Portal was used to explore 
the connectivity of resveratrol associated genes across all 
prostate cancer studies available in the databases. Through 
use of the portal search function, resveratrol associated 
genes in all samples of prostate cancer studies are 
classified as altered or not altered. The genomics datasets 
are then presented using OncoPrint as heatmaps — a 
visually appealing display of alterations in gene arrays 
across tumor samples [46]. Another feature of the portal 
is that it can generate multiple visualization platforms by 
grouping prostate cancer data alterations using input from 
resveratrol gene sets [46–50].
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